Matthew Shaulis, Chief Commercial Officer and US President, Hansa Biopharma AB, has decided to leave the company in late September. Effective immediately, the Commercial Leadership team will report to Søren Tulstrup, President and CEO. A search is underway for a new CCO and US President.
 
Søren Tulstrup, President and CEO, Hansa Biopharma remarked, “Matt has been a fantastic addition to the Hansa executive team and has made significant contributions across the organization over the past years. I want to thank Matt for his commitment and dedication to advancing key priorities including commercialization efforts in Europe, acceleration of our ConfIdeS US pivotal study, and the initiation of launch planning in the US, and we wish him well in his new endeavor.
 
This news comes a year after Hansa restructured its organization to better align and focus on key clinical development and commercial priorities—including an approximately 20-25% reduction in its workforce.
 
More recently, Hansa appointed Evan Ballantyne as Chief Financial Officer (CFO).